Sugi Predict

Sugi Predict / Compounds / SCHEMBL9638313

SCHEMBL9638313

SCHEMBL9638313

COc1ccc(O)c(-c2ccccc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ KDM4E B2RXH2 2/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ BACE1 P56817 4/20 0.59
▸ NCOA1 Q15788 1/20 0.54
▸ NCOA3 Q9Y6Q9 1/20 0.54
▸ NPC1 O15118 3/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ PTPN1 P18031 2/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ NFKB2 Q00653 1/20 0.51
▸ RELA Q04206 1/20 0.51
▸ HDAC8 Q9BY41 2/20 0.50
▸ GUSB P08236 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29541984 0.88 KMT2A (0.61) MAPTSMN1; SMN2KDM4EMAPK1BACE1
SCHEMBL11192923 0.86 BACE1 (0.66) MAPTSMN1; SMN2KDM4EMAPK1BACE1
SCHEMBL589665 0.84 BACE1 (0.60) MAPTSMN1; SMN2KDM4EMAPK1BACE1
SCHEMBL29763172 0.83 NPC1 (0.61) MAPTSMN1; SMN2KDM4EMAPK1NPC1
SCHEMBL8440252 0.83 NPC1 (0.61) MAPTSMN1; SMN2KDM4EMAPK1NPC1
SCHEMBL22264586 0.83 BACE1 (0.67) MAPTSMN1; SMN2MAPK1BACE1NCOA1
SCHEMBL30504173 0.83 BACE1 (0.67) MAPTSMN1; SMN2MAPK1BACE1NCOA1
SCHEMBL9068308 0.82 NPC1 (0.53) MAPTSMN1; SMN2KDM4EMAPK1NPC1
SCHEMBL9817035 0.82 BACE1 (0.53) MAPTSMN1; SMN2KDM4EMAPK1BACE1
SCHEMBL9713026 0.82 BACE1 (0.53) MAPTSMN1; SMN2KDM4EMAPK1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115038730-B Resin composition for photofabrication 可乐丽则武齿科株式会社 2024-12-24 — — CN disclosed
CN-118922164-A Adhesive composition for both light-molded article and non-light-molded article 可乐丽则武齿科株式会社 2024-11-08 — — CN disclosed
CN-114072439-B Curable composition and resin composition for photofabrication comprising same 株式会社可乐丽 2024-05-14 — — CN disclosed
CN-113993497-B Curable composition and resin composition for photofabrication comprising same 株式会社可乐丽 2024-03-22 — — CN disclosed
CN-116669679-A Adhesive composition for photo-molded article 可乐丽则武齿科株式会社 2023-08-29 — — CN disclosed
WO-2023120611-A1 CURABLE DENTAL COMPOSITION クラレノリタケデンタル株式会社 2023-06-29 — — WO disclosed
CN-114940697-A Method for constructing C-S structure by accurately modifying tryptophan indole C-2 position under catalysis of visible light and application of method 兰州大学 2022-08-26 — — CN disclosed
CN-111377963-B Method for preparing thiophosphine compound through visible light-promoted dehydrogenation coupling reaction 中国科学院兰州化学物理研究所 2021-09-03 — — CN disclosed
CN-108913122-B Cyanide ion supramolecular sensor and synthesis and application thereof in fluorescence recognition of cyanide 西北师范大学 2021-03-23 — — CN disclosed
CN-107226807-B Tankyrase inhibitors 北京四环制药有限公司 2021-01-01 — — CN disclosed
US-20170296548-A1 DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS GENFIT (FR) 2017-10-19 — — US disclosed
US-9586963-B2 Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists GENFIT (FR) 2017-03-07 — — US disclosed
CN-104530548-B Halogen-free transparent flame-retardant photovoltaic encapsulating material and preparation method of halogen-free transparent flame-retardant photovoltaic encapsulating material 杭州福斯特光伏材料股份有限公司 2017-02-22 — — CN disclosed
US-20150038503-A1 DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS GENFIT (FR) 2015-02-05 — — US disclosed
EP-2760866-A1 DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS Genfit (FR) 2014-08-06 — — EP disclosed
WO-2013045519-A1 DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS GENFIT (FR) 2013-04-04 — — WO disclosed
CN-1327881-A Catalyst precursor composition DU PONT (US) 2001-12-26 — — CN disclosed
EP-0246114-B1 PHOTOCHROMIC SPIROPYRAN COMPOUNDS GEC-MARCONI LIMITED (GB) 1992-09-02 — — EP disclosed
US-4826977-A Photochromic spiropyran compounds THE PLESSEY COMPANY PLC (GB) 1989-05-02 — — US disclosed
EP-0246114-A2 Photochromic spiropyran compounds GEC-MARCONI LIMITED (GB) 1987-11-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170296548-A1 DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS NR1D1, NR1D2, PER2 MAPT 3765/4885SMN1; SMN2 4539/4885KDM4E 1135/4885
US-20150038503-A1 DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS NR1D1, NR1D2, PER2 MAPT 3765/4885SMN1; SMN2 4539/4885KDM4E 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.